

## COVID-19 Pediatric Admission Order Set

Print as needed and always include Side B of applicable pages (content may change rapidly).

Select orders by placing a (✓) in the associated box

|   |  |                                  |  |
|---|--|----------------------------------|--|
| Last Name (Legal)   |  | First Name (Legal)               |  |
| Preferred Name <input type="checkbox"/> Last <input type="checkbox"/> First |  | DOB (dd-Mon-yyyy)                |  |
| PHN   | ULI <input type="checkbox"/> Same as PHN | MRN                              |  |
| Administrative Gender <input type="checkbox"/> Male                         |  | <input type="checkbox"/> Female  |  |
| <input type="checkbox"/> Non-binary/Prefer not to disclose (X)              |  | <input type="checkbox"/> Unknown |  |

|   |                             |   |              |
|---|-----------------------------|---|--------------|
| <b>Admission</b>  |                             |   |              |
| <input type="checkbox"/> Admit to Inpatient Service:  |                             |   |              |
| <b>Goals of Care</b>  |                             |   |              |
| <i>Should be addressed upon admission</i>   |                             |   |              |
| <input type="checkbox"/> R1   | <input type="checkbox"/> M1 | <input type="checkbox"/> C1                                 |              |
| <input type="checkbox"/> R2   | <input type="checkbox"/> M2 | <input type="checkbox"/> C2                                 |              |
| <input type="checkbox"/> R3   |                             |   |              |
| <b>Screening</b>  |                             |   |              |
| <input checked="" type="checkbox"/> Respiratory Viral Pathogen Testing (Includes COVID-19)  |                             |   |              |
| <i>Must complete the following laboratory requisition; COVID-19 and Other Respiratory Viruses (Form #21701) with required clinical history and criteria to ensure timely processing of test <a href="https://www.albertahealthservices.ca/frm-21701.pdf">https://www.albertahealthservices.ca/frm-21701.pdf</a></i>   |                             |   |              |
| <i>For ID NOW COVID-19 testing, follow local processes if available at your site.</i>   |                             |   |              |
| <b>Isolation</b>  |                             |   |              |
| <input checked="" type="checkbox"/> Initiate Contact and Droplet Isolation for suspected or positive COVID-19 (acute respiratory illness)   |                             |   |              |
| <input checked="" type="checkbox"/> Wear fit tested N95 respirator and move to private room ONLY when performing Aerosol-generating medical procedures (AGMP)   |                             |   |              |
| <b>Respiratory Interventions</b>  |                             |   |              |
| <i>If Aerosol-Generating Medical Procedures (AGMP) required - place patient in a private room with hard walls and a closed door, all staff to use N-95 respirators during AGMP. Refer to AGMP look up tool: <a href="http://ahsweb.ca/HEE/AGMP_Guidance_Tool">http://ahsweb.ca/HEE/AGMP_Guidance_Tool</a>. If oxygen requirements are rapidly increasing consider early consultation with Critical Care or RAAPID transfer.</i> |                             |   |              |
| <input checked="" type="checkbox"/> Oxygen Therapy – Titrate to Saturation  |                             |   |              |
| • Children: titrate to target SpO <sub>2</sub> between 92% to 96%   |                             |   |              |
| <b>Initial O<sub>2</sub> delivery method:</b>   |                             |   |              |
| <input type="checkbox"/> Nasal Prongs   |                             |   |              |
| <input type="checkbox"/> Simple face mask (non-humidified)  |                             |   |              |
| <input type="checkbox"/> Face mask with reservoir/non-rebreather (non-humidified)   |                             |   |              |
| <b>Patient Care</b>   |                             |   |              |
| <input type="checkbox"/> Vital Signs (Temperature, Blood pressure, Heart rate, Respiratory rate, SpO <sub>2</sub> ) every 4 hours   |                             |   |              |
| <input type="checkbox"/> Cardio-respiratory Monitoring; continuous  |                             |   |              |
| <input type="checkbox"/> Pulse Oximetry (specify): <input type="checkbox"/> Intermittent <input type="checkbox"/> Continuous  |                             |   |              |
| <input type="checkbox"/> Weigh patient (specify): <input type="checkbox"/> Daily <input type="checkbox"/> other: _____  |                             |   |              |
| <input type="checkbox"/> Measure Height on admission  |                             |   |              |
| <input type="checkbox"/> Adjust Head of Bed to at least 30 degrees  |                             |   |              |
| <input type="checkbox"/> Notify Most Responsible Health Practitioner if increasing O <sub>2</sub> requirements, rapidly progressive respiratory failure or sepsis (follow local Early Warning System policy as applicable)  |                             |   |              |
| <input type="checkbox"/> Activity (specify): <input type="checkbox"/> No Activity Restrictions <input type="checkbox"/> Strict Bed Rest   |                             |   |              |
| <b>Diet and Nutrition</b> - If clinically appropriate oral feeds are preferred over IV. If unable to tolerate or deteriorating, IV fluids are preferred as opposed to NG. Consider NPO for patients in respiratory distress or with high oxygen requirements.   |                             |   |              |
| <input type="checkbox"/> NPO  |                             | <input type="checkbox"/> Enteral Nutrition (specify): _____ |              |
| <input type="checkbox"/> Age appropriate pediatric diet   |                             | <input type="checkbox"/> Other diet _____                   |              |
| <input type="checkbox"/> Breast milk or bottle fed ad lib   |                             |   |              |
| Prescriber Name   | Prescriber Signature        | Date (dd-Mon-yyyy)  | Time (hh:mm) |

## COVID-19 Pediatric Admission Order Set

For current Clinical Guidance refer to the following links:

Care of the Hospitalized Pediatric Patient with COVID-19 Inpatient Guideline  
[https://ahsweb.ca/HEE/Care\\_of\\_the\\_hospitalized\\_pediatric\\_patient\\_with\\_Covid\\_19](https://ahsweb.ca/HEE/Care_of_the_hospitalized_pediatric_patient_with_Covid_19)

Care of the Pediatric Critically Ill COVID-19 Patient Annex E  
[https://ahsweb.ca/HEE/Care\\_of\\_the\\_critically\\_ill\\_pediatric\\_patient\\_with\\_Covid\\_19](https://ahsweb.ca/HEE/Care_of_the_critically_ill_pediatric_patient_with_Covid_19)

AHS COVID-19 Insite Page  
[http://ahsweb.ca/HEE/AHS\\_Insite\\_COVID-19](http://ahsweb.ca/HEE/AHS_Insite_COVID-19)

Recommendations for Antimicrobial Management of Pediatric Hospitalized Patients with COVID-19  
[http://ahsweb.ca/HEE/AHS\\_Recommendations\\_for\\_Antimicrobial\\_Management\\_of\\_Pediatric\\_Hospitalized\\_Patients\\_with\\_COVID-19](http://ahsweb.ca/HEE/AHS_Recommendations_for_Antimicrobial_Management_of_Pediatric_Hospitalized_Patients_with_COVID-19)

Interim IPC Recommendation during COVID-19  
[http://ahsweb.ca/HEE/Interim\\_IPC\\_Recommendations\\_during\\_COVID-19](http://ahsweb.ca/HEE/Interim_IPC_Recommendations_during_COVID-19)

### Clinical Decision Support

Signs and symptoms are similar to those of a typical Influenza-like Illness.

| <b>Classification of severity of COVID-19 in children:</b>  |   |
|---|---|
| <i>Note there is not yet consensus on this categorization; these are based on literature to date and guidelines for experimental treatments. It is recognized these categories do not match typical severities of ILI</i> |   |
| Mild Disease  | <ul style="list-style-type: none"> <li>Upper respiratory symptoms (e.g., pharyngeal congestion, sore throat, and fever) for a short duration or asymptomatic infection</li> <li>Positive RT-PCR test for SARS-CoV-2</li> <li>May also include fatigue, myalgia, and gastrointestinal symptoms</li> </ul>  |
| Moderate Disease  | <ul style="list-style-type: none"> <li>Clinical and/ or radiological signs of pneumonia on chest imaging</li> <li>Symptoms such as fever, cough, fatigue, headache, and myalgia</li> <li>No complications and manifestations related to severe conditions</li> </ul>  |
| Severe Disease  | Mild or moderate clinical features, plus any manifestations that suggest disease progression: <ul style="list-style-type: none"> <li>Worsening tachypnea</li> <li>Hypoxemia (oxygen saturation less than 92 % on room air)</li> <li>Altered level of consciousness, such as Irritability or lethargy</li> <li>Dehydration, difficulty feeding, gastrointestinal dysfunction</li> </ul>  |
| Critical Disease  | Rapid disease progression, plus any other conditions: <ul style="list-style-type: none"> <li>Respiratory failure with need for mechanical ventilation (e.g., ARDS, persistent hypoxia despite non-invasive oxygen supplementation)</li> <li>Decreased level of consciousness, depression, coma, convulsions</li> <li>Myocardial injury</li> <li>Elevated liver enzymes</li> <li>Coagulation dysfunction, rhabdomyolysis, and any other manifestations suggesting injuries to vital organs</li> <li>Septic shock</li> <li>Other evidence of organ failure</li> </ul> |

**Treatment is generally supportive.** Strict isolation precautions in keeping with AHS IPC guidelines are to be maintained.

## COVID-19 Pediatric Admission Order Set

|   |  |   |  |
|---|--|---|--|
| Last Name (Legal)   |  | First Name (Legal)  |  |
| Preferred Name <input type="checkbox"/> Last <input type="checkbox"/> First         |  | DOB (dd-Mon-yyyy)   |  |
| PHN   | ULI <input type="checkbox"/> Same as PHN | MRN   |  |
| Administrative Gender <input type="checkbox"/> Male <input type="checkbox"/> Female |  | <input type="checkbox"/> Non-binary/Prefer not to disclose (X) <input type="checkbox"/> Unknown |  |

Select orders by placing a (✓) in the associated box

| Laboratory Investigations  |  |  |                                    |
|--|--|--|------------------------------------|
| <b>Basic</b> (not routinely recommended for mild disease)  |  |  |                                    |
| <input type="checkbox"/> CBC and Differential  | <input type="checkbox"/> Aspartate Aminotransferase (AST)                      | <input type="checkbox"/> Glucose, random |                                    |
| <input type="checkbox"/> Creatinine  | <input type="checkbox"/> Alanine Aminotransferase (ALT)                        | <input type="checkbox"/> Urea            |                                    |
| <input type="checkbox"/> Bilirubin, Total  | <input type="checkbox"/> Electrolytes (Na, K, Cl, CO <sub>2</sub> , Anion Gap) | <input type="checkbox"/> Blood Cultures  |                                    |
| <input type="checkbox"/> C-Reactive Protein  |  |  |                                    |
| <b>Second Line</b> (literature does not support a specific role of these parameters in guiding clinical management but they may be useful in prognostication)  |  |  |                                    |
| <input type="checkbox"/> Triglycerides   | <input type="checkbox"/> Lactate Dehydrogenase                                 | <input type="checkbox"/> Fibrinogen      | <input type="checkbox"/> D-dimer   |
| <input type="checkbox"/> Ferritin  | <input type="checkbox"/> Troponin  | <input type="checkbox"/> INR             | <input type="checkbox"/> Cytokines |
| <input type="checkbox"/> Blood Gas Capillary   |  |  |                                    |
| COVID-19 Serology  |  |  |                                    |
| <p><b>If a COVID-19 NAT positive patient at least 12 years old, greater than 40 kg, is unvaccinated or immunocompromised, admitted to hospital, had no previous history of COVID-19 infection and is considered for treatment with casirivimab/imdevimab, then COVID-19 serology is indicated.</b></p> <p>Recommend Consultation to Pediatric Infectious Diseases.</p> <p>Supply is limited for casirivimab-imdevimab (REGEN-COV). Discretion around ordering based on AHS formulary criteria is advised. This test is restricted based on site.</p> <p><b>If testing will be conducted in regional hospital-based APL labs in High Level, Grande Prairie, Fort McMurray, Red Deer, Lethbridge or Medicine Hat, CHOOSE:</b></p> <p><input type="checkbox"/> Rapid COVID-19 Serology, STAT</p> <p><b>If testing will be conducted in Edmonton Zone or Calgary Zone, CHOOSE:</b></p> <p><input type="checkbox"/> COVID-19 Serology, STAT</p> <p>Result can only be obtained during day-shift hours (0730-1600). After hours testing is not available.<br/>Ensure tube is labelled with ProvLab Monoclonal Antibody</p> |  |  |                                    |
| Diagnostic Imaging - CTs are not often used in pediatrics due to risks associated with ionizing radiation  |  |  |                                    |
| <input type="checkbox"/> Chest X-ray portable  |  |  |                                    |
| Cardiology - Consider in severe or critical COVID-19   |  |  |                                    |
| <input type="checkbox"/> Electrocardiogram, 12-lead  |  |  |                                    |
| <input type="checkbox"/> Pediatric Transthoracic Echocardiogram (TTE) Limited  |  |  |                                    |
| <input type="checkbox"/> Pediatric Transthoracic Echocardiogram (TTE) Complete   |  |  |                                    |
| IV Fluids - Conservative fluid management strategies for children are recommended. Consider limiting total fluid intake to 75% maintenance.  |  |  |                                    |
| <input type="checkbox"/> Pediatric Total Fluid Intake (TFI) _____  |  |  |                                    |
| <input type="checkbox"/> NaCl 0.9% infusion IV bolus _____ mL or IV maintenance at (specify rate): _____   |  |  |                                    |
| <input type="checkbox"/> NaCl 0.9% 20 mmol KCl per 1000 mL infusion IV maintenance at (specify rate): _____  |  |  |                                    |
| <input type="checkbox"/> D5-NaCl 0.9% infusion IV maintenance at (specify rate): _____   |  |  |                                    |
| <input type="checkbox"/> D5-NaCl 0.9% 20 mmol KCl per 1000 mL infusion IV maintenance at (specify rate): _____   |  |  |                                    |
| <input type="checkbox"/> Other Fluid (specify type): _____ at (specify rate): _____  |  |  |                                    |
| Prescriber Name  | Prescriber Signature   | Date (dd-Mon-yyyy)                       | Time (hh:mm)                       |

## COVID-19 Pediatric Admission Order Set

|   |  |                                  |  |
|---|--|----------------------------------|--|
| Last Name (Legal)   |  | First Name (Legal)               |  |
| Preferred Name <input type="checkbox"/> Last <input type="checkbox"/> First |  | DOB (dd-Mon-yyyy)                |  |
| PHN   | ULI <input type="checkbox"/> Same as PHN | MRN                              |  |
| Administrative Gender <input type="checkbox"/> Male                         |  | <input type="checkbox"/> Female  |  |
| <input type="checkbox"/> Non-binary/Prefer not to disclose (X)              |  | <input type="checkbox"/> Unknown |  |

Select orders by placing a (✓) in the associated box

| <b>Medications - refer to side B of page 2 for additional medication guidance</b>  |                      |                    |              |
|--|----------------------|--------------------|--------------|
| <b>Antibiotics</b>   |                      |                    |              |
| <i>Recommended if patient critically ill, at risk of early deterioration, suspicion of secondary bacterial pneumonia, or sepsis.</i>   |                      |                    |              |
| <b><u>Moderate Illness</u></b>   |                      |                    |              |
| <i>Recommended dosage for amoxicillin: 45-90 mg/kg/day divided every 8 hours.</i>  |                      |                    |              |
| <i>Higher dose to be used if there are risk factors for resistant Streptococcus pneumoniae: Unimmunized or incompletely immunized, attends daycare, use of amoxicillin in preceding 3 months, failure of initial therapy</i>   |                      |                    |              |
| <input type="checkbox"/> amoxicillin 50 mg/mL liquid oral _____ mg PO TID  |                      |                    |              |
| <b>OR</b>  |                      |                    |              |
| <i>Recommended dose for ampicillin 200-400 mg/kg/day every 24 hours or divided q6hrs</i>   |                      |                    |              |
| <input type="checkbox"/> ampicillin injection _____ mg IV every 6 hours  |                      |                    |              |
| <b>If the clinical and epidemiological presentation is in keeping with M. pneumonia disease, consider Azithromycin</b>   |                      |                    |              |
| <i>Recommended azithromycin dose is 10 mg/kg/dose once on Day 1 followed by 5 mg/kg/dose daily for 4 days (5 days total).</i>  |                      |                    |              |
| <input type="checkbox"/> AZithromycin _____ mg once on DAY 1: <input type="checkbox"/> PO <input type="checkbox"/> IV  |                      |                    |              |
| <b>FOLLOWED BY</b>   |                      |                    |              |
| <input type="checkbox"/> AZithromycin _____ mg daily for 4 days: <input type="checkbox"/> PO <input type="checkbox"/> IV   |                      |                    |              |
| <b><u>Severe Illness</u></b>   |                      |                    |              |
| <i>Recommended dose for ceftriaxone 50-75 mg/kg/dose every 24 hours or divided every 12hrs</i>   |                      |                    |              |
| <input type="checkbox"/> cefTRIAxone IV _____ mg, every _____ hours, first dose STAT   |                      |                    |              |
| <b><u>Critical Illness: consider addition of vancomycin</u></b>  |                      |                    |              |
| <i>Recommended dose for vancomycin 15 mg/kg/dose every 6 hours</i>   |                      |                    |              |
| <input type="checkbox"/> vancomycin _____ mg IV every 6 hours  |                      |                    |              |
| <b>Antivirals - Not routinely recommended for COVID-19. Infectious Diseases consultation recommended except for Tamiflu in treatment of Influenza.</b>   |                      |                    |              |
| <i>Oseltamivir can be used for Influenza (suspected or confirmed) without ID consult and should ideally be started within 48 hours of symptom onset. For severe hospital or ICU cases during Influenza season it is recommended even beyond 48 hours of symptom onset.</i> |                      |                    |              |
| <i>Recommended dose for oseltamivir in children and adolescents:</i>   |                      |                    |              |
| 15 kg or less - 30 mg  |                      |                    |              |
| 15 to 23 kg - 45 mg  |                      |                    |              |
| 23 to 40 kg - 60 mg  |                      |                    |              |
| greater than 40 kg - 75 mg   |                      |                    |              |
| <input type="checkbox"/> oseltamivir 6 mg/ml PO _____ mg: <input type="checkbox"/> liquid <input type="checkbox"/> capsule every: <input type="checkbox"/> day <input type="checkbox"/> BID  |                      |                    |              |
| Prescriber Name  | Prescriber Signature | Date (dd-Mon-yyyy) | Time (hh:mm) |

## COVID-19 Pediatric Admission Order Set

|   |  |                                  |  |
|---|--|----------------------------------|--|
| Last Name (Legal)   |  | First Name (Legal)               |  |
| Preferred Name <input type="checkbox"/> Last <input type="checkbox"/> First |  | DOB (dd-Mon-yyyy)                |  |
| PHN   | ULI <input type="checkbox"/> Same as PHN | MRN                              |  |
| Administrative Gender <input type="checkbox"/> Male                         |  | <input type="checkbox"/> Female  |  |
| <input type="checkbox"/> Non-binary/Prefer not to disclose (X)              |  | <input type="checkbox"/> Unknown |  |

Select orders by placing a (✓) in the associated box

| Medications Continued   |                      |                    |              |
|---|----------------------|--------------------|--------------|
| <p><b>Antivirals - Not routinely recommended for COVID-19. Infectious Diseases consultation recommended except for Tamiflu in treatment of Influenza.</b></p> <p><i>Oseltamivir can be used for Influenza (suspected or confirmed) without ID consult and should ideally be started within 48 hours of symptom onset. For severe hospital or ICU cases during Influenza season it is recommended even beyond 48 hours of symptom onset.</i></p> <p><i>Recommended dose for oseltamivir in children and adolescents:</i></p> <p style="padding-left: 40px;">15 kg or less - 30 mg</p> <p style="padding-left: 40px;">15 to 23 kg - 45 mg</p> <p style="padding-left: 40px;">23 to 40 kg - 60 mg</p> <p style="padding-left: 40px;">greater than 40 kg - 75 mg</p> <p><input type="checkbox"/> oseltamivir 6 mg/ml PO _____ mg:    <input type="checkbox"/> liquid    <input type="checkbox"/> capsule    every:    <input type="checkbox"/> day    <input type="checkbox"/> BID</p>  |                      |                    |              |
| <p><b>Immunomodulatory</b></p> <p><i>Consider casirivimab/imdevimab if patient greater than 12 years of age, unvaccinated, seronegative, no prior COVID-19 infection OR if patient immunocompromised. <b>Not for use in confirmed or suspected omicron variant cases due to documented loss of neutralizing activity.</b></i></p> <p><i>Recommend consultation to Pediatric Infectious Disease.</i></p> <p><i>Consider tocilizumab OR baricitinib if admission less than 7 days, significant respiratory failure requiring high-flow nasal cannula, ventilation (invasive or non-invasive) less than 24 hours previous.</i></p> <p><i>Recommend consultation to Pediatric Infectious Disease.</i></p> <p>AHS Formulary – tocilizumab: <a href="https://ahsweb.ca/HEE/ahs_formulary_tocilizumab">https://ahsweb.ca/HEE/ahs_formulary_tocilizumab</a></p> <p>AHS Formulary – baricitinib: <a href="https://ahsweb.ca/HEE/ahs_formulary_baricitinib">https://ahsweb.ca/HEE/ahs_formulary_baricitinib</a></p> <p>Manual: COVID-19 Immunomodulator Orders:<br/><a href="https://manual.connect-care.ca/home/hot-topics/covid-19/covid-19-decision-supports/covid-19-tocilizumab-orders">https://manual.connect-care.ca/home/hot-topics/covid-19/covid-19-decision-supports/covid-19-tocilizumab-orders</a></p> <p>AHS Formulary casirivimab/imdevimab: <a href="https://ahsweb.ca/HEE/ahs_formulary_casirivimab_imdevimab">https://ahsweb.ca/HEE/ahs_formulary_casirivimab_imdevimab</a></p> <p>Manual: COVID-19 Neutralizing Antibodies Orders:<br/><a href="https://manual.connect-care.ca/home/hot-topics/covid-19/covid-19-decision-supports/covid-19-casirivimab-imdevimab-orders">https://manual.connect-care.ca/home/hot-topics/covid-19/covid-19-decision-supports/covid-19-casirivimab-imdevimab-orders</a></p> <p><input type="checkbox"/> _____</p> |                      |                    |              |
| <p><b>Glucocorticoids</b></p> <p><b>Glucocorticoids should be considered in hospitalized patients who meet criteria for severe disease including those that require supplemental oxygen.</b></p> <p>Please refer to the Care of the Hospitalized Pediatric Patient with COVID-19 provincial guideline for definition of Severe disease.<br/><a href="https://ahsweb.ca/HEE/Care_of_the_hospitalized_pediatric_patient_with_Covid_19">https://ahsweb.ca/HEE/Care_of_the_hospitalized_pediatric_patient_with_Covid_19</a></p> <p><input type="checkbox"/> dexAMETHasone injection for oral use (0.15 mg/kg/dose, Max 6 mg) _____ mg PO daily x 10 days.</p> <p><b>OR</b></p> <p><input type="checkbox"/> dexAMETHasone tab (0.15 mg/kg/dose, Max 6 mg) _____ mg PO daily x 10 days</p> <p><b>OR</b></p> <p><input type="checkbox"/> dexAMETHasone (0.15 mg/kg/dose, Max 6 mg) _____ mg IV daily x 10 days</p>   |                      |                    |              |
| Prescriber Name   | Prescriber Signature | Date (dd-Mon-yyyy) | Time (hh:mm) |

## COVID-19 Pediatric Admission Order Set

Select orders by placing a (✓) in the associated box

|   |  |                                  |  |
|---|--|----------------------------------|--|
| Last Name <i>(Legal)</i>  |  | First Name <i>(Legal)</i>        |  |
| Preferred Name <input type="checkbox"/> Last <input type="checkbox"/> First |  | DOB <i>(dd-Mon-yyyy)</i>         |  |
| PHN   | ULI <input type="checkbox"/> Same as PHN | MRN                              |  |
| Administrative Gender <input type="checkbox"/> Male                         |  | <input type="checkbox"/> Female  |  |
| <input type="checkbox"/> Non-binary/Prefer not to disclose (X)              |  | <input type="checkbox"/> Unknown |  |

### Consults/Referrals

- Consult to Pediatric Critical Care
- Consult to Pediatric Infectious Disease
- Consult to Pediatric Respiratory Medicine
- Consult to Pediatric Cardiology
- Consult to Pediatric Rheumatology
- Consult *(specify)*: \_\_\_\_\_

### Discharge Follow up

- Patient/caregiver to book follow-up with their Primary Care Provider in 1 to 3 days post-discharge as per clinical assessment

|                 |                      |                           |                     |
|-----------------|----------------------|---------------------------|---------------------|
| Prescriber Name | Prescriber Signature | Date <i>(dd-Mon-yyyy)</i> | Time <i>(hh:mm)</i> |
|                 |                      |                           |                     |